Dr. Madden obtained his BSc. and Ph.D. in Biochemistry from the University of London, U.K. He has held senior academic and industry positions including Assistant Professor in Pharmacology at the University of British Columbia and Senior Director, Technology Development and Licensing at Tekmira Pharmaceuticals. At Tekmira Pharmaceuticals Dr. Madden was responsible for product development of several liposomal anticancer agents including Marqibo™ (liposomal vincristine). Dr. Madden founded Acuitas Therapeutics in February 2009 and through his role as President and CEO has guided the company in its corporate relationships. The collaboration he established with Alnylam Pharmaceuticals resulted in development of key delivery technology that has been translated into two RNAi therapeutics in clinical development. Dr. Madden has over 50 publications relating to LNP technology and development of pharmaceutical products.